Jan 02, 2020
Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China
Sep 24, 2019
Amgen Announces Positive Results From Two Phase 3 BLINCYTO® (blinatumomab) Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia
Jun 16, 2019
Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019
Feb 19, 2019
Arix Bioscience plc: Autolus Announces Updated Results From CARPALL Trial
Feb 19, 2019
Autolus Therapeutics Announces Updated Results from Ongoing CARPALL Trial of Pediatric Acute Lymphoblastic Leukemia Presented at the EHA 1st European CAR T Cell Meeting in Paris
Jan 22, 2019
European Commission Approves BLINCYTO® (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia
Sep 24, 2018
BLINCYTO® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia
Aug 29, 2018
European Commission Approves BLINCYTO® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Jun 19, 2018
Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO® (blinatumomab) Label
Mar 29, 2018
FDA Approves BLINCYTO® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children
Feb 14, 2018
Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO® (blinatumomab)
Jun 23, 2017
European Hematology Association: The More the T-lymphocytes Differ, the More Effectively They Fight Against Leukemia